Menu

 

Task Book: Biological & Physical Sciences Division and Human Research Program
Advanced Search     

Project Title:  Effects of Angiotensin Converting Enzyme Inhibitors (ACEI) on Bone Turnover Reduce
Fiscal Year: FY 2016 
Division: Human Research 
Research Discipline/Element:
HRP HHC:Human Health Countermeasures
Start Date: 10/01/2013  
End Date: 12/31/2015  
Task Last Updated: 03/23/2016 
Download report in PDF pdf
Principal Investigator/Affiliation:   Rianon, Nahid  M.D. / University of Texas Houston Health Science Center 
Address:  Internal Medicine, Div of Geriatrics & Palliative Medicine 
6431 Fannin St 
Houston , TX 77030-1501 
Email: Nahid.J.Rianon@uth.tmc.edu 
Phone: 832-878-0614  
Congressional District:
Web:  
Organization Type: UNIVERSITY 
Organization Name: University of Texas Houston Health Science Center 
Joint Agency:  
Comments:  
Co-Investigator(s)
Affiliation: 
Smith, Scott  NASA Johnson Space Center 
Project Information: Grant/Contract No. NNX13AQ92G 
Responsible Center: NASA ARC 
Grant Monitor: Ronca, April  
Center Contact: 650.604.3595 
april.e.ronca-1@nasa.gov 
Solicitation / Funding Source: 2012 Crew Health NNJ12ZSA002N 
Grant/Contract No.: NNX13AQ92G 
Project Type: GROUND 
Flight Program:  
TechPort: No 
No. of Post Docs:
No. of PhD Candidates:
No. of Master's Candidates:
No. of Bachelor's Candidates:
No. of PhD Degrees:
No. of Master's Degrees:
No. of Bachelor's Degrees:
Human Research Program Elements: (1) HHC:Human Health Countermeasures
Human Research Program Risks: (1) Osteo:Risk Of Early Onset Osteoporosis Due To Spaceflight (No longer used, July 2020)
Human Research Program Gaps: (1) Osteo07:We need to identify options for mitigating early onset osteoporosis before, during and after spaceflight (IRP Rev E)
Flight Assignment/Project Notes: NOTE: Extended to 12/31/2015 per A. Chu/ARC and NSSC information (Ed., 7/28/15)

NOTE: Extended to 9/30/2015 (original end date was 9/30/2014) per NSSC information and A. Chu/ARC (Ed., 9/10/14)

Task Description: Antihypertensive medications affecting the renin-angiotensin system (RAS), specifically angiotensin converting enzyme inhibitor (ACEI), have been documented to decrease bone turnover in animals, and improved bone mineral density (BMD) in preliminary human studies. We propose a randomized trial to collect pilot data in 30 men and 30 women (15 treated with ACEI and 15 not treated with RAS related medications) to investigate if ACEI prevents bone loss by decreasing bone turnover. We hypothesize that ACEI use for 3 months to treat hypertension (HTN) in older adults will decrease bone turnover by decreasing bone resorption, the primary factor in spaceflight induced bone loss. These results could provide another tool in protecting bone health of astronauts, using a pharmacological agent with very few side effects, which is a significant concern of agents currently being tested. Further, these data may also help understand variability in existing spaceflight data, where crewmembers may have taken antihypertensive medications, which may have confounded results of ongoing studies. Beyond NASA, the clinical implications of this study for the general population are significant.

Research Impact/Earth Benefits: Provide knowledge of prevention in bone loss due to old age.

Task Progress & Bibliography Information FY2016 
Task Progress: We were able to recruit 32 patients with hypertension – 22 of them were female and 10 of them were male.

A total of 9 males (with 4 without exposure to ACEi and 5 with exposure to ACEi) and 15 females (10 without exposure to ACEi and 5 with exposure to ACEi) (total N = 24) completed the study with 3 month follow up visit.

We have completed DXA (dual-energy X-ray absorptiometry) bone density tests in spine and hip regions at baseline for the participants.

We have completed serum sample analysis and data entry from the chart review. Data analysis is pending at this time. We plan to publish after completion of data analysis.

Bibliography Type: Description: (Last Updated: )  Show Cumulative Bibliography Listing
 
 None in FY 2016
Project Title:  Effects of Angiotensin Converting Enzyme Inhibitors (ACEI) on Bone Turnover Reduce
Fiscal Year: FY 2015 
Division: Human Research 
Research Discipline/Element:
HRP HHC:Human Health Countermeasures
Start Date: 10/01/2013  
End Date: 12/31/2015  
Task Last Updated: 11/12/2014 
Download report in PDF pdf
Principal Investigator/Affiliation:   Rianon, Nahid  M.D. / University of Texas Houston Health Science Center 
Address:  Internal Medicine, Div of Geriatrics & Palliative Medicine 
6431 Fannin St 
Houston , TX 77030-1501 
Email: Nahid.J.Rianon@uth.tmc.edu 
Phone: 832-878-0614  
Congressional District:
Web:  
Organization Type: UNIVERSITY 
Organization Name: University of Texas Houston Health Science Center 
Joint Agency:  
Comments:  
Co-Investigator(s)
Affiliation: 
Smith, Scott  NASA Johnson Space Center 
Project Information: Grant/Contract No. NNX13AQ92G 
Responsible Center: NASA ARC 
Grant Monitor: Ronca, April  
Center Contact: 650.604.3595 
april.e.ronca-1@nasa.gov 
Solicitation / Funding Source: 2012 Crew Health NNJ12ZSA002N 
Grant/Contract No.: NNX13AQ92G 
Project Type: GROUND 
Flight Program:  
TechPort: No 
No. of Post Docs:
No. of PhD Candidates:
No. of Master's Candidates:
No. of Bachelor's Candidates:
No. of PhD Degrees:
No. of Master's Degrees:
No. of Bachelor's Degrees:
Human Research Program Elements: (1) HHC:Human Health Countermeasures
Human Research Program Risks: (1) Osteo:Risk Of Early Onset Osteoporosis Due To Spaceflight (No longer used, July 2020)
Human Research Program Gaps: (1) Osteo07:We need to identify options for mitigating early onset osteoporosis before, during and after spaceflight (IRP Rev E)
Flight Assignment/Project Notes: NOTE: Extended to 12/31/2015 per A. Chu/ARC and NSSC information (Ed., 7/28/15)

NOTE: Extended to 9/30/2015 (original end date was 9/30/2014) per NSSC information and A. Chu/ARC (Ed., 9/10/14)

Task Description: Antihypertensive medications affecting the renin-angiotensin system (RAS), specifically angiotensin converting enzyme inhibitor (ACEI), have been documented to decrease bone turnover in animals, and improved bone mineral density (BMD) in preliminary human studies. We propose a randomized trial to collect pilot data in 30 men and 30 women (15 treated with ACEI and 15 not treated with RAS related medications) to investigate if ACEI prevents bone loss by decreasing bone turnover. We hypothesize that ACEI use for 3 months to treat hypertension (HTN) in older adults will decrease bone turnover by decreasing bone resorption, the primary factor in spaceflight induced bone loss. These results could provide another tool in protecting bone health of astronauts, using a pharmacological agent with very few side effects, which is a significant concern of agents currently being tested. Further, these data may also help understand variability in existing spaceflight data, where crewmembers may have taken antihypertensive medications, which may have confounded results of ongoing studies. Beyond NASA, the clinical implications of this study for the general population are significant.

Research Impact/Earth Benefits: Provide knowledge of prevention in bone loss due to old age.

Task Progress & Bibliography Information FY2015 
Task Progress: Last 12 months:

• Institutional Review Board (IRB) approval received

• Started recruitment and continuing recruitment

• IRB continuing review approved

• Received approval for “No cost extension” of the project - see following schedule for revised plan of action:

Recruit subjects: August 2014-May 2015

Test subjects: September 2014-June 2015

Ship samples: June 2015

Sample/data analysis: June 2015-September 2015

Writeup: September 2015-October 2015

Bibliography Type: Description: (Last Updated: )  Show Cumulative Bibliography Listing
 
 None in FY 2015
Project Title:  Effects of Angiotensin Converting Enzyme Inhibitors (ACEI) on Bone Turnover Reduce
Fiscal Year: FY 2014 
Division: Human Research 
Research Discipline/Element:
HRP HHC:Human Health Countermeasures
Start Date: 10/01/2013  
End Date: 09/30/2015  
Task Last Updated: 09/11/2013 
Download report in PDF pdf
Principal Investigator/Affiliation:   Rianon, Nahid  M.D. / University of Texas Houston Health Science Center 
Address:  Internal Medicine, Div of Geriatrics & Palliative Medicine 
6431 Fannin St 
Houston , TX 77030-1501 
Email: Nahid.J.Rianon@uth.tmc.edu 
Phone: 832-878-0614  
Congressional District:
Web:  
Organization Type: UNIVERSITY 
Organization Name: University of Texas Houston Health Science Center 
Joint Agency:  
Comments:  
Co-Investigator(s)
Affiliation: 
Smith, Scott  NASA Johnson Space Center 
Project Information: Grant/Contract No. NNX13AQ92G 
Responsible Center: NASA ARC 
Grant Monitor: Ronca, April  
Center Contact: 650.604.3595 
april.e.ronca-1@nasa.gov 
Solicitation / Funding Source: 2012 Crew Health NNJ12ZSA002N 
Grant/Contract No.: NNX13AQ92G 
Project Type: GROUND 
Flight Program:  
TechPort: No 
No. of Post Docs:  
No. of PhD Candidates:  
No. of Master's Candidates:  
No. of Bachelor's Candidates:  
No. of PhD Degrees:  
No. of Master's Degrees:  
No. of Bachelor's Degrees:  
Human Research Program Elements: (1) HHC:Human Health Countermeasures
Human Research Program Risks: (1) Osteo:Risk Of Early Onset Osteoporosis Due To Spaceflight (No longer used, July 2020)
Human Research Program Gaps: (1) Osteo07:We need to identify options for mitigating early onset osteoporosis before, during and after spaceflight (IRP Rev E)
Flight Assignment/Project Notes: NOTE: Extended to 9/30/2015 (original end date was 9/30/2014) per NSSC information and A. Chu/ARC (Ed., 9/10/14)

Task Description: Antihypertensive medications affecting the renin-angiotensin system (RAS), specifically angiotensin converting enzyme inhibitor (ACEI), have been documented to decrease bone turnover in animals, and improved BMD in preliminary human studies. We propose a randomized trial to collect pilot data in 30 men and 30 women (15 treated with ACEI and 15 not treated with RAS related medications) to investigate if ACEI prevents bone loss by decreasing bone turnover. We hypothesize that ACEI use for 3 months to treat hypertension (HTN) in older adults will decrease bone turnover by decreasing bone resorption, the primary factor in spaceflight induced bone loss. These results could provide another tool in protecting bone health of astronauts, using a pharmacological agent with very few side effects, which is a significant concern of agents currently being tested. Further, these data may also help understand variability in existing spaceflight data, where crewmembers may have taken antihypertensive medications, which may have confounded results of ongoing studies. Beyond NASA, the clinical implications of this study for the general population are significant.

Research Impact/Earth Benefits: 0

Task Progress & Bibliography Information FY2014 
Task Progress: New project for FY2014.

Bibliography Type: Description: (Last Updated: )  Show Cumulative Bibliography Listing
 
 None in FY 2014